Anjali Sharma, MD

Anjali is a Pediatric Hematologist-Oncologist who trained at Lucile Packard Children’s
Hospital, Stanford. During her fellowship, she also completed a fellowship in Adult Bone Marrow and Stem Cell transplant at Stanford Medical center. She earned her medical degree from Lady Hardinge Medical School in New Delhi, India and completed her pediatric residency at the University of Illinois, Chicago.

Following fellowship, she worked at University of California, San Francisco in the Pediatric Bone Marrow and Stem Cell Transplant Division. She subsequently joined Kaiser Permanente, where she served as an attending physician in the Division of Pediatric Hematology- Oncology, covering the SF bay area.

In 2015, she transitioned to industry, joining Amgen as the U.S. Medical Lead in Medical Affairs for Aranesp and Nplate. She moved into clinical development in 2017 as a Clinical Research Medical director and, in 2019, became an Early Development Lead, overseeing two early hematology-oncology development teams.

In 2021, Anjali joined CRISPR therapeutics as the Global Development Lead for the Thalassemia trial of CTX 001( Exa-cel) gene therapy. She later returned to oncology as the Global Development Lead for CTX 130, a CD70-directed allogeneic CAR-T cell therapy. Most recently, she served as the Pediatric Oncology Global Development Lead at Gilead Sciences.

Currently, she is a Pediatric Hematology-Oncology Consultant at A9 Clinical Consultants, a firm she founded. In this role, she provides expert biotech consulting services with a focus on pediatric hematology-oncology, gene therapy, and cellular therapy.